HERS Protocol 5 — Hepatic Encephalopathy Recovery & Support

HE in Acute Liver FailureDrug-Induced, Viral, and Sudden-Onset Liver Failure — Recognition and Recovery


← Back to main protocol
Acute liver failure (ALF) is a distinct medical emergency requiring hospital-level care. This protocol is not a substitute for that care. Its purpose is to help patients and families understand what ALF is, what to communicate to the care team, and how to support recovery after the acute phase has been managed. The post-acute supplement and dietary guidance in this protocol is designed for the recovery trajectory specific to ALF — which is meaningfully more optimistic than cirrhosis-related HE when the underlying cause is removed.
🚨 Acute Liver Failure Is a Medical Emergency

If the person does not yet have a diagnosis and is showing signs of jaundice, confusion, or abdominal pain developing rapidly over days to weeks without a history of known chronic liver disease — go to the emergency room and use these words:

"I am concerned about acute liver failure. There is new jaundice, confusion, and [symptoms]. They have/may have taken [acetaminophen / medication / herbal supplement]. Please check INR, liver enzymes, and ammonia."

ALF can progress from early symptoms to life-threatening illness within days. The window for intervention — particularly for acetaminophen-induced ALF — is hours, not days.

What Is Acute Liver Failure?

Acute liver failure (ALF) is defined as rapid loss of liver function in a person without pre-existing liver disease — typically over days to weeks. Unlike cirrhosis-related HE, which develops on a foundation of chronic liver damage, ALF is a sudden collapse of otherwise healthy liver tissue. This distinction matters enormously: the trajectory is completely different, and in many cases the liver can fully recover if the cause is identified and removed in time.

Common Causes

Acetaminophen (Tylenol)
Most common cause in the US and UK. Intentional overdose or unintentional therapeutic excess. Most recoverable with prompt treatment.
Drug-Induced (non-acetaminophen)
Antibiotics (amoxicillin-clavulanate, isoniazid), NSAIDs, statins, antiepileptics, herbal supplements.
Viral Hepatitis A or E
Hepatitis A and E can cause ALF in adults — rare but real. Hepatitis B reactivation also causes ALF.
Autoimmune Hepatitis
Autoimmune attack on liver cells — can present acutely and responds to immunosuppression.
Acute Wilson's Disease
Rare copper metabolism disorder, often presenting in young adults.
Pregnancy-Related
HELLP syndrome, acute fatty liver of pregnancy — obstetric emergencies requiring immediate delivery.

Acetaminophen ALF — Time Is Liver

Acetaminophen-induced ALF is the most common and most recoverable form. The mechanism is well-understood: at toxic doses, acetaminophen's metabolite (NAPQI) accumulates and destroys hepatocytes. The specific antidote — N-acetylcysteine (NAC) — works by replenishing glutathione, which neutralizes NAPQI.

N-Acetylcysteine (NAC) is the treatment — it must be given in hospital via IV.

The efficacy window is time-sensitive: NAC is most effective within the first 8–10 hours of ingestion but has demonstrated benefit even in late-presenting cases. The King's College criteria (based on pH, INR, creatinine, and HE grade) guide decisions about transplant listing — a family member who understands this can ask the right questions.

What to tell the ER: State the approximate amount taken, the time of ingestion (even approximately), and whether any other medications or alcohol were involved. Acetaminophen levels drawn at the right time interval are used to determine treatment necessity — timing of the level matters.

How ALF-Related HE Differs from Cirrhosis HE

The HE in ALF is mechanistically similar — elevated ammonia, astrocyte dysfunction — but the trajectory and clinical context are different in important ways:

Cerebral edema is a greater concern in ALF than in cirrhosis. In ALF, the rapid ammonia rise can cause astrocyte swelling severe enough to increase intracranial pressure — a risk that is much less prominent in the gradual ammonia elevation of cirrhosis. ICU monitoring for signs of raised intracranial pressure (abnormal posturing, pupillary changes, hypertension with bradycardia) is a standard part of ALF management.

Coagulopathy is prominent. ALF impairs all clotting factor production, creating bleeding risk. This affects what interventions can be safely performed and what medications are safe.

The liver may recover fully. In acetaminophen ALF that is treated promptly, and in many cases of viral or drug-induced ALF once the cause is removed, the liver can regenerate to near-normal function. The outcome potential is genuinely better than in cirrhotic HE.

Protein intake may need to be more cautious acutely — in severe ALF with rapidly escalating HE and cerebral edema risk, moderate short-term protein restriction (not zero) may be recommended by the ICU team. This is a legitimate acute-phase exception to the general "avoid protein restriction" principle — follow the clinical team's guidance during the acute hospital phase, and return to 1.2–1.5g/kg/day during recovery.

Post-Acute Recovery Protocol

Once the acute phase has been managed and liver function is recovering, the post-discharge approach has important differences from the main cirrhosis protocol. A recovering liver that is regenerating has different needs than one managing chronic fibrosis:

Bowel Management — If HE Persists Post-Discharge
MiraLax (Polyethylene Glycol 3350)
1 capful daily — titrate to 2–3 soft stools per day. Continue until HE fully resolves.
If HE is still present at discharge, bowel management remains relevant and MiraLax remains the best-tolerated option. As liver function recovers and HE resolves, MiraLax can be tapered — it is not indefinitely required in ALF recovery the way it is in cirrhosis.
Liver Regeneration Support
N-Acetylcysteine (NAC) — oral post-discharge
600mg twice daily for 4–8 weeks post-discharge (discuss duration with discharging provider)
NAC supports glutathione synthesis and has antioxidant and anti-inflammatory properties beyond its role as NAPQI antidote. Post-acute oral NAC has been studied for hepatoprotection and liver regeneration support after ALF. It is safe, inexpensive, and well-tolerated orally. Available over the counter as a supplement (NAC 600mg capsules are widely available).

Note for acetaminophen cases: Continuing oral NAC after hospital discharge supports ongoing glutathione repletion during liver regeneration. This is a reasonable, low-risk intervention with a plausible ongoing benefit.
Ammonia Support — If HE Still Present
LOLA (L-Ornithine L-Aspartate)
Start 6g/day and titrate toward 18g/day as tolerated, while HE symptoms are present. Can be reduced as liver function normalizes.
LOLA supports residual urea cycle function during recovery. As the liver regenerates, ammonia clearance normalizes and LOLA can be gradually discontinued — unlike cirrhosis cases where it may be needed indefinitely. LOLA is a bridge intervention here, not a permanent one.
Sourcing: BulkSupplements.com — pharmaceutical-grade LOLA powder, COA available, digital scale needed for dosing.
Liver Regeneration Support
Milk Thistle (Silymarin)
420–560mg daily (standardized to 70–80% silymarin)
Silymarin has the most established hepatoprotective evidence among botanical supplements. Mechanisms include antioxidant activity, anti-inflammatory effects, and direct stimulation of hepatocyte protein synthesis — supporting regeneration. Multiple RCTs and a Cochrane review have examined it in various liver diseases. Evidence is modest but consistent with safety and some benefit. In the post-ALF recovery context — where the liver is actively regenerating rather than chronically damaged — silymarin's direct hepatoprotective and regenerative mechanisms are most applicable.

Important caveat: Silymarin is a mild CYP3A4 inhibitor. If other medications are being taken, verify there are no interactions.
Antioxidant Support
Vitamin E (alpha-tocopherol)
400 IU daily with a fat-containing meal
Oxidative stress is a central mechanism in both ALF and the recovery phase. Vitamin E at moderate doses (400 IU) supports hepatocyte protection during regeneration. Note that the higher 800 IU NASH-specific dose is less relevant here; 400 IU is appropriate for general hepatoprotection in the recovery context.
Protein and Nutritional Recovery
Casein + Frequent meals + BCAAs
Return to 1.2–1.5g protein/kg/day as HE resolves. BCAAs 12–20g/day. No fasting beyond 4 hours.
During the acute ICU phase, protein intake may have been modified. Post-acute recovery requires returning to adequate protein intake to support both muscle preservation and active liver regeneration — the liver uses amino acids as building blocks for cellular repair. The recovering liver is metabolically active and needs substrate.
Micronutrient Repletion
B-50 Complex + Thiamine 100mg + Zinc 25mg + Magnesium Glycinate 400mg
As described in main protocol
ALF depletes micronutrients rapidly through the inflammatory and metabolic crisis. Repletion supports the enzymatic machinery of liver regeneration. Zinc is a cofactor for over 300 enzymes including those involved in hepatocyte repair. Thiamine supports energy metabolism in the regenerating tissue.

What to Avoid During Recovery

Acetaminophen — after acetaminophen-induced ALF, this is obvious. After other-cause ALF, acetaminophen can be reintroduced at low doses (max 2g/day) once liver enzymes have normalized — earlier resumption carries risk.

Alcohol — inhibits liver regeneration directly. Even if the original ALF was not alcohol-related, alcohol should be avoided completely during recovery.

Herbal supplements and botanicals (other than those listed) — multiple herbal supplements have documented hepatotoxicity (kava, comfrey, pyrrolizidine alkaloids, pennyroyal, green tea extract in high doses). During a recovering liver, introduce supplements one at a time and cautiously.

NSAIDs — worsen kidney function and hepatorenal stress in recovery.

New prescription medications without pharmacist review — many common drugs are hepatically metabolized; during recovery, dosing may need adjustment.

Recovery Monitoring

Liver function tests (LFTs) should be repeated at regular intervals post-discharge — ALT, AST, bilirubin, INR. Improving trends confirm regeneration. Worsening or plateau warrants urgent hepatology review.

Asterixis check: In ALF recovery, resolution of asterixis is one of the clearest markers of improving ammonia clearance as the liver regenerates. Returning asterixis is a significant sign that should prompt immediate contact with the care team.

Jaundice trend: Gradually fading jaundice confirms recovery. Stable or worsening jaundice warrants review.

Energy and cognitive function: These are the most practically meaningful recovery markers. ALF recovery typically follows a trajectory of weeks, not days. Cognitive fog persisting beyond 6–8 weeks warrants hepatology follow-up.

Signs Requiring Immediate Return to Care

✓ ALF Recovery — Realistic Expectations

Acute liver failure, particularly when caused by acetaminophen and treated promptly, has a genuinely favorable prognosis in many cases. The liver has remarkable regenerative capacity — unlike the fibrotic scarring of cirrhosis, ALF in a previously healthy liver leaves minimal permanent damage when the cause is removed and recovery is supported.

Most patients who recover from ALF without transplant do not develop cirrhosis. Full functional recovery is achievable. The recovery period is weeks to a few months, not years. This is meaningful and worth holding onto during the hard parts.

Acute liver failure is terrifying precisely because it is sudden — people who were well become critically ill within days. But it is also one of the most recoverable severe liver conditions when recognized early and managed appropriately. The protocol above is for the post-acute phase: supporting a liver that is trying to rebuild itself, and giving it the nutritional and biochemical environment to do that well.
Key References

Lee WM et al. Acute liver failure: Summary of a workshop. Hepatology, 2008.

Goh ET et al. LOLA for HE in cirrhosis. Cochrane Database, 2018.

Rahimi RS et al. Lactulose vs PEG 3350 for Overt HE. JAMA Internal Medicine, 2014.

Rambaldi A et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases. Cochrane Database, 2007.

Squires RH et al. Acute liver failure in children: The first 348 patients. Journal of Pediatrics, 2006.

Brok J et al. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database, 2006.